BioTime launches all-stock bid to acquire Geron's stalled stem cell programme
This article was originally published in Clinica
Executive Summary
After hiring Geron's former president and CEO to run an acquisition-focused subsidiary, BioTime has made a public bid for the regenerative medicine programme that Geron put on hold almost a year ago, offering an all-stock deal for embryonic stem cell technology previously investigated as a treatment for acute spinal cord injuries.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.